GlassScriptPhysician profile
Wilson Benjamin Nino
NPI 1760989743
$831.65
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $758 · 2022: $73.78.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $281.93 | 2021-2022 | |
| Esperion Therapeutics, INC. | $161.34 | 2021 | |
| Lilly USA, LLC | $125.98 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $91.56 | 2021 | |
| Janssen Pharmaceuticals, INC | $58.25 | 2021 | |
| Amarin Pharma, INC. | $39.96 | 2021 | |
| Glaxosmithkline, LLC. | $21.10 | 2022 | |
| Sanofi-Aventis U.S. LLC | $19.83 | 2021 | |
| Acerus Pharmaceuticals Corporation | $16.96 | 2021 | |
| Arbor Pharmaceuticals, INC. | $14.74 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wilson Nino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.